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Abstract
Background: Mice with a deleted Cav1 gene encoding caveolin-1 develop adipocyte abnormalities
and insulin resistance. From genomic DNA of patients with atypical lipodystrophy and
hypertriglyceridemia who had no mutations in any known lipodystrophy gene, we used DNA
sequence analysis to screen the coding regions of human CAV1 (MIM 601047).
Results: We found a heterozygous frameshift mutation in CAV1, designated I134fsdelA-X137, in a
female patient who had atypical partial lipodystrophy, with subcutaneous fat loss affecting the upper
part of her body and face, but sparing her legs, gluteal region and visceral fat stores. She had severe
type 5 hyperlipoproteinemia, with recurrent pancreatitis. In addition, she had some atypical
features, including congenital cataracts and neurological findings. Her father was also heterozygous
for this mutation, and had a similar pattern of fat redistribution, hypertriglyceridemia and congenital
cataracts, with milder neurological involvement. An unrelated patient had a different heterozygous
frameshift mutation in the CAV1 gene, designated -88delC. He also had a partial lipodystrophy
phenotype, with subcutaneous fat loss affecting the arms, legs and gluteal region, but sparing his
face, neck and visceral fat stores. He also had severe type 5 hyperlipoproteinemia, with recurrent
pancreatitis; however he had no clinically apparent neurological manifestations. The mutations
were absent from the genomes of 1063 healthy individuals.
Conclusion: Thus, very rare CAV1 frameshift mutations appear to be associated with atypical
lipodystrophy and hypertriglyceridemia.
Background
Lipodystrophies are a heterogeneous group of diseases
that result in abnormal fat distribution and severe insulin
resistance [1-5]. The molecular basis for several forms of
partial and complete lipodystrophy syndromes have been
characterized [6], but some patients with inherited lipod-
ystrophies do not have mutations in the known lipodys-
trophy genes. Finding other candidate genes for
evaluation can be challenging because the families of such
probands are often small, so positional cloning (or link-
age analysis) using genome-wide marker sets cannot be
performed. Another approach to find causative mutations
is to select human candidate genes by analogy from genes
that have been manipulated in animal models with a
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comparable phenotype. For instance, mice with induced
deficiency in Cav1 encoding the cell surface protein cave-
olin-1 (MIM 601047) showed depleted and abnormal
adipocytes with insulin resistance and severe hypertriglyc-
eridemia [7-9]. Since no human mutations in CAV1 have
yet been reported, we screened the genomic DNA of 60
unrelated adults with partial lipodystrophy and hypertrig-
lyceridemia and no mutation in any known lipodystro-
phy gene to search for coding sequence mutations in
CAV1.
Results
Demographics of study sample
From a tertiary referral lipid clinic, we evaluated 60
patients (80% female) who had partial lipodystrophy,
with diabetes or moderate to severe (type 4 or 5) hyper-
triglyceridemia. Age, body mass index, untreated fasting
plasma cholesterol and triglycerides (mean+standard
deviation [SD]) were, respectively, 52.5 ± 14.0 years, 26.2
± 3.8 kg/m2, 6.9 ± 5.0 mmol/L and 11.1+10.0 mmol/L. All
subjects consented to DNA analysis. No coding sequence
mutations were found in LMNA,  PPARG,  BSCL2  or
AGPAT2 genes encoding nuclear lamin A/C, peroxisome
proliferator-activated receptor gamma, seipin or 1-acyl-
sn-glycerol-3-phosphate acetyltransferase, respectively.
Characterization of patients with CAV1 mutations
Two rare heterozygous coding sequence variants in CAV1
were found among the screened patients, I134fsdelA-
X137 in one patient and -88delC in another (Figure 1).
These frameshift mutations were absent from the
genomes of 1063 normolipidemic control subjects. The
I134fsdelA-X137 mutation predicted premature termina-
tion, with loss of the carboxy terminal half of the protein
product. This mutation was subsequently found in the
proband's father, who had a similar phenotype. The -
88delC mutation occurred within the 5'-untranslated
region with a potential effect on the reading frame. The
clinical features of the father and daughter with the heter-
ozygous I134fsdelA-X137 mutation and the singleton
patient with the heterozygous -88delC mutation are sum-
marized in Table 1.
The history and clinical features of the I134fsdelA-X137
mutation proband (Patient A) and her affected father
(Patient B) have been previously reported [10]. Briefly,
the proband, who was assessed at age 28 years, was a
woman of Northern European origin who was wheelchair
bound since early adulthood. At birth, she was noted to
have a lack of facial and upper body subcutaneous fat,
micrognathia and congenital cataracts. Later, diplopia,
tinnitus and a central auditory processing defect were
noted. She had severe type 5 hyperlipoproteinemia with
recurrent pancreatitis; she had insulin resistance but no
diabetes. On examination, she was noted to have orthos-
tatic hypotension, a high arched palate, taut skin with
sparing of subcutaneous fat on buttocks, hips and thighs.
She was noted also to have webbed toes, acanthosis nigri-
cans, retinitis pigmentosa, iris deposits, marked nystag-
mus, ocular dysmetria, past-pointing on finger-nose
testing, dysdiadochokinesis, a spastic-ataxic gait, sponta-
neous clonus of legs, bilateral Babinski signs, reduced
power in the lower extremity and lost vibration sense in a
glove-and-stocking distribution. She had leg spasms, a
stiff gait, paresthesiae, imbalance and urinary inconti-
nence. Investigations showed lipemic plasma with mark-
edly elevated serum cholesterol (9.3 mmol/L) and
triglycerides (20.4 mmol/L). Her father (Patient B), a 55
year old diabetic man of Northern European origin, had
similar body fat distribution to his daughter. He also had
congenital cataracts and retinitis pigmentosa, but no neu-
rological complaints, and was ambulatory and well-func-
tioning. On examination, he was noted to have absent
facial, neck, and limb fat with increased abdominal and
lower back subcutaneous fat. He also had decreased sen-
sation in both legs, with normal muscle power and tone;
an unsteady narrow-based gait was elicited. He had milder
biochemical abnormalities than his daughter, with mild
hypertriglyceridemia and no history of pancreatitis. Of
note, Patient B's sister (the paternal aunt of Patient A)
died from an undefined neurological condition at age 40.
Medical records showed a clinical presentation similar to
Patient A, with analogous fat redistribution, leg weakness
and ataxia beginning at age 18 and requirement for a
wheelchair at age 20 [10]. Patient C, a heterozygote for the
CAV1 -88delC mutation, was 35 years old at assessment.
He was noted in his early 20's to have redistributed fat
stores, with a relative loss of subcutaneous fat on his arms,
gluteal region, thighs and calves and increased visceral fat
on abdominal ultrasound examination. He had severe
hypertriglyceridemia (range 10 to 80 mmol/L) beginning
in his late 20's, with recurrent episodes of pancreatitis. He
was diagnosed with diabetes at age 33 and currently takes
120 units of insulin daily in addition to fenofibrate 200
mg daily. Physical examination revealed fat redistribu-
tion, with no ocular, neurological, dermatologic or musc-
uloskeletal findings.
Discussion
Caveolin-1 is expressed in numerous tissues and is a cen-
tral component of cell surface caveoli, which are plasma
membrane microdomains that regulate signaling path-
ways and processes such as cell migration, polarization,
proliferation and especially endocytosis [11-13]. Cav1
appears to have a significant role in murine adipocyte
metabolism, and disruption of the gene leads to severe
hypertriglyceridemia, insulin resistance and adipocyte
abnormalities, which are all features that are consistent
with human partial lipodystrophy [7-9]. Our genetic find-
ings suggest that CAV1 might also have a role in humanLipids in Health and Disease 2008, 7:3 http://www.lipidworld.com/content/7/1/3
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adipose, insulin and triglyceride metabolism, albeit only
two frameshift mutations in CAV1 were found among 60
lipodystrophic patients with a normal coding sequence of
known lipodystrophy genes.
The frameshift mutations would be expected to result in a
compromised gene product from the affected allele. The
I134fsdelA-X137 mutation co-segregated with the pheno-
type from father to daughter, but the more severe pheno-
type in the daughter suggests that other factors – perhaps
genetic or non-genetic – can modulate the severity of the
phenotype. The presence of a comparably severe pheno-
type in Patient A's paternal aunt suggests that gender
might also modulate the severity of phenotypic expres-
sion in carriers. Also, the variable organ system involve-
ment – the ocular and central nervous systems in Patients
A and B but not in Patient C – is consistent with the vari-
able multi-system phenotypes seen in Cav1 deficient mice
depending on genetic background [11-13]. However, het-
erozygous Cav1 deficient mice do not show any pheno-
type, again suggesting that other factors are required for
phenotypic expression in these patients. Unfortunately,
we could not further extend the families in order to docu-
ment phenotypes seen in other CAV1 mutation carriers at
present, although this is planned for the future.
Conclusion
The association of these rare frameshift mutations in
CAV1 with atypical presentations of partial lipodystrophy
with insulin resistance and hypertriglyceridemia, the
absence of these mutations from healthy controls together
with evidence from mouse models link the CAV1 gene
with human metabolic phenotypes. Since only two muta-
tions were found among 60 screened subjects, CAV1
mutations are a very rare cause of lipodystrophy and
hypertriglyceridemia.
Table 1: Clinical and biochemical features of atypical lipodystrophy patients with CAV1 mutations
Attribute Patient A Patient B Patient C
Ancestry Northern Europe Northern Europe Northern Europe
CAV1 mutation name I134fsdelA-X137 I134fsdelA-X137 -88delC
age at assessment (years) 28 55 35
sex female male male
lipodystrophy onset birth birth adulthood
BMI (kg/m2) 25.0 24.5 25.6
waist circumference (cm) 86 88 92
Subcutaneous fat changes:
face decrease decrease increase
arms decrease decrease decrease
gluteal region increase increase decrease
thighs increase increase decrease
calves increase increase decrease
visceral increase increase increase
age of diabetes onset (years) none 30 33
hypertension and age of onset none none 33
hyperlipoproteinemia type 5 type 4 type 5
pancreatitis recurrent no recurrent
highest historical plasma triglyceride 20.4 mmol/L 80 mmol/L 16.5 mmol/L
acanthosis nigricans present absent present
congenital cataracts bilateral bilateral absent
atypical retinitis pigmentosa bilateral bilateral absent
tinnitus moderate absent absent
nystagmus severe absent absent
spastic ataxia severe mild absent
dysdiadochokinesia severe mild absent
muscle power in lower limbs diminished (4/5) normal normal
sensory glove/stocking neuropathy severe mild absent
Babinski sign bilateral absent absent
finger past-pointing severe absent absent
other comments wheel-chair bound since age 20; similarly 
affected paternal aunt (deceased)
Patient A's father; legally blind requires 120 U of insulin dailyLipids in Health and Disease 2008, 7:3 http://www.lipidworld.com/content/7/1/3
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Methods
Genomic DNA analysis
The exons and intron-exon boundaries of CAV1  were
amplified and bi-directionally sequenced using the prim-
ers and conditions in Table 2. All coding sequence muta-
tions were confirmed by a second sequencing reaction
performed on another day. The frequency of the CAV1
exon 3 I134fsdelA-X137 variant was determined in
healthy control subjects using genomic DNA amplifica-
tion with primers 5'-ATG GAT ACT GAA TAG TGG GTT
TTT and 5'-TGT TGC TGT ATT AGC AAC TTG GA. The 509
bp product was digested with restriction enzyme NsiI
(New England Biolabs, Mississauga, ON) and fragments
were resolved on 2% agarose gels. The digested fragments
of the wild-type allele were 280 and 229 base pairs (bp) in
size, while the digested fragment of the mutant allele was
509 bp in size. The frequency of the CAV1 exon 1 -88delC
variant was determined in healthy control subjects using
genomic DNA amplification with primers 5'-AG ATG ATG
CAC TGG GAA AA and 5'-CTA GGC CCC CTC TCC ATT
AG, with allele specific diagnostic (SNaPShot) primer 5'-
GAT CTT GTA TTG TAT GGG GG.
Electropherogram scans showing the novel heterozygous CAV1 frameshift mutations in the lipodystrophy patients Figure 1
Electropherogram scans showing the novel heterozygous CAV1 frameshift mutations in the lipodystrophy patients. The left half 
of the figure shows a portion of CAV1 exon 2 from genomic DNA of a control subject and Patient A. The right half of the figure 
shows a portion of CAV1 5' untranslated region (5'UTR) from genomic DNA of a control subject and Patient C. For each trac-
ing, normal nucleotide sequence is shown in the top line of letters, with single letter amino acid codes and codon numbers 
beneath for exon sequence. The position of each inserted nucleotide is indicated by the arrows for the respective mutations 
I134fsdelA-X137 and -88delC.
Control
Patient A
Control
Patient C
Control
Patient A
Control
Patient C
I134fsdelA-X137 -88delC
Table 2: Primers used for sequencing CAV1
Exon Primers Fragment size (nucleotide base pairs)
1 F-5' GAG ATG ATG CAC TGG GAA AA
R-5' CTA GGC CCC CTC TCC ATT AG
633
2 F-5' GTA GCT GTC GGA GCG GTT AG
R-5' GGA GCT CCC ACA CAT CAA AC
480
3 F-5' ATG GAT ACT GAA TAG TGG GTT TTT
R-5' TGT TGC TGT ATT AGC AAC TTG GA
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